<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVES: <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease is a <z:e sem="disease" ids="C0559758" disease_type="Disease or Syndrome" abbrv="">multisystem disorder</z:e> characterized by a <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mp ids='MP_0001845'>inflammation</z:mp> including <z:hpo ids='HP_0011009'>acute</z:hpo> attacks and remission periods </plain></SENT>
<SENT sid="1" pm="."><plain>Decreased enzyme activity of the <z:chebi fb="11" ids="22586">antioxidant</z:chebi> system and increased levels of free radicals may have important roles in the damage of tissues observed in the disease period </plain></SENT>
<SENT sid="2" pm="."><plain>In addition, the atherogenic tendency of serum <z:chebi fb="23" ids="18059">lipid</z:chebi>, <z:chebi fb="2" ids="6495">lipoproteins</z:chebi>, <z:chebi fb="23" ids="18059">lipid</z:chebi> peroxidation levels and <z:e sem="disease" ids="C0856169" disease_type="Disease or Syndrome" abbrv="">endothelial dysfunction</z:e> accompany the above mentioned findings </plain></SENT>
<SENT sid="3" pm="."><plain>As a consequence of these events, different degrees of <z:chebi fb="2" ids="39026">low density lipoprotein</z:chebi> (<z:chebi fb="15" ids="39026">LDL</z:chebi>) oxidation occur in vivo, and then autoantibodies against oxidized-<z:chebi fb="15" ids="39026">LDL</z:chebi>(AuAb-oxLDL) are produced </plain></SENT>
<SENT sid="4" pm="."><plain>DESIGN AND METHODS: <z:chebi fb="23" ids="18059">Lipids</z:chebi>, <z:chebi fb="2" ids="6495">lipoproteins</z:chebi>, <z:chebi fb="23" ids="18059">lipid</z:chebi> <z:chebi fb="0" ids="35923">hydroperoxide</z:chebi>, AuAb-oxLDL, total <z:chebi fb="11" ids="22586">antioxidant</z:chebi> status (TAS), serum-soluble intercellular <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule-1 (sICAM-1), plasminogen activator inhibitor 1 (PAI-1) levels in serum, the activities of <z:chebi fb="11" ids="22586">antioxidant</z:chebi> enzymes including <z:chebi fb="0" ids="16856">glutathione</z:chebi> peroxidase (GSH-Px), <z:chebi fb="0" ids="16856">glutathione</z:chebi> reductase (GR), <z:chebi fb="1" ids="18421">superoxide</z:chebi> dismutase (SOD), and catalase (CAT) in erythrocytes and plasma, were determined in 25 patients with <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease and in 25 healthy volunteers </plain></SENT>
<SENT sid="5" pm="."><plain>Also, susceptibility to copper-induced in vitro oxidation of <z:chebi fb="15" ids="39026">LDL</z:chebi> by using lag time, a measure of resistance to oxidation, oxidation rate and extent of oxidation, a measure of diene production in both groups, was studied </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: It was observed that <z:chebi fb="23" ids="18059">lipid</z:chebi> <z:chebi fb="0" ids="35923">hydroperoxide</z:chebi> and AuAb-oxLDL levels in patients with <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease were significantly higher, but erythrocyte SOD, CAT, plasma GSH-Px activities, and TAS were significantly lower than those in healthy subjects </plain></SENT>
<SENT sid="7" pm="."><plain>Susceptibility of <z:chebi fb="15" ids="39026">LDL</z:chebi> to oxidation in the patients was found to be increased </plain></SENT>
<SENT sid="8" pm="."><plain>Total cholesterol, <z:chebi fb="0" ids="47774">LDL-C</z:chebi> and apo B levels and <z:hpo ids='HP_0011009'>acute</z:hpo> phase reactants were significantly higher, but <z:chebi fb="0" ids="47775">HDL-C</z:chebi> and apo AI levels were significantly lower, in patients when compared to healthy subjects </plain></SENT>
<SENT sid="9" pm="."><plain>The levels of AuAb-oxLDL in patients were found to correlate with TAS, total cholesterol, <z:chebi fb="0" ids="47774">LDL-C</z:chebi>, <z:chebi fb="23" ids="18059">lipid</z:chebi> <z:chebi fb="0" ids="35923">hydroperoxide</z:chebi> and erythrocyte SOD activities (r = -0.62, p &lt; 0.01; r = 0.64, p &lt; 0.01; r = 0.55, p &lt; 0.01; r = 0.81, p &lt; 0.01; r = -0.63, p &lt; 0.01, respectively) </plain></SENT>
<SENT sid="10" pm="."><plain>In addition, <z:chebi fb="23" ids="18059">lipid</z:chebi> <z:chebi fb="0" ids="35923">hydroperoxide</z:chebi> levels were found to correlate with total cholesterol, <z:chebi fb="0" ids="47774">LDL-C</z:chebi> and erythrocyte SOD activities (r = 0.45, p &lt; 0.05; r = 0.45, p &lt; 0.05; r = -0.46, p &lt; 0.05, respectively) </plain></SENT>
<SENT sid="11" pm="."><plain>PAI-1 and sICAM-1 were found to be increased in the patients and correlated with AuAb-oxLDL and <z:chebi fb="23" ids="18059">lipid</z:chebi> <z:chebi fb="0" ids="35923">hydroperoxide</z:chebi> levels (r = 0.56, p &lt; 0.01; r = 0.67, p &lt; 0.01 and r = 0.59, p &lt; 0.01; r = 0.61, p &lt; 0.01, respectively) </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: It was concluded that the observed increase of <z:chebi fb="23" ids="18059">lipid</z:chebi>, <z:chebi fb="2" ids="6495">lipoproteins</z:chebi>, <z:chebi fb="23" ids="18059">lipid</z:chebi> <z:chebi fb="0" ids="35923">hydroperoxide</z:chebi>, susceptibility of <z:chebi fb="15" ids="39026">LDL</z:chebi> to oxidation, autoantibodies against ox-<z:chebi fb="15" ids="39026">LDL</z:chebi> levels and decrease of <z:chebi fb="11" ids="22586">antioxidant</z:chebi> enzyme activities and total <z:chebi fb="11" ids="22586">antioxidant</z:chebi> status and increased secretion of endothelial derivated <z:chebi fb="7" ids="16670">peptides</z:chebi> including sICAM and PAI-1, and their interactions may indicate that there is a tendency to atherothrombotic events in patients with <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease </plain></SENT>
</text></document>